Rose McNulty

A retrospective study assessed hospital readmission rates in patients with sickle cell disease and acute chest syndrome who took angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers vs those who did not.

Improved management of sickle cell disease has vastly improved life expectancy and reduced morbidity for affected patients, but the disease itself and its treatments carry fertility risks that many young patients and their caregivers are unaware of.

Very elderly patients with acute myeloid leukemia have historically been limited to less intensive, less effective treatment regimens. A recent series of cases suggests age alone should not be a limiting factor for effective treatment.

A study of hospitals and long-term care facilities in Louisville, Kentucky, found low rates of Clostridioides difficile testing in patients with new-onset diarrhea who are frequently infected.

Patients with acute myeloid leukemia (AML) who have undergone intensive chemotherapy are at a very high risk for invasive fungal disease, and a changing treatment landscape warrants further research on drug-drug interactions and outcomes.

Polycythemia vera and essential thrombocythemia are both slow-progressing conditions and treated mainly with symptom management, but novel agents and gene targets have changed the landscape in recent years.

Preventing health-care–associated infections in acute-care hospitals is crucial for patient well-being and health care cost burden, and comprehensive guidelines based on current research are an important aspect of prevention.

Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel combination approach may hold promise in future treatments.

Peer support can be a helpful facet of chronic kidney disease (CKD) self-management, but inconsistent provider awareness and referral practices are barriers to uptake at Canadian clinics.

A study of the Austrian general population found that most chronic cough cases could be assigned a phenotype through a simple survey-based assessment that could help target treatment to individual cases.

While risk factors for pterygia are well-known, the underlying disease mechanisms have not been fully clarified in past studies. A new analysis using RNA sequencing pinpointed ptergyia-specific biomarkers and potential therapeutic targets.

A recent study found chronic kidney disease (CKD) to be an independent risk factor for incident heart failure with reduced ejection fraction (HFrEF) following percutaneous coronary intervention (PCI).

Acute myeloid leukemia is a complicated heterogenous hematological cancer with a poor prognosis, but novel targets may lead to improved treatment and outcomes going forward.

Previous studies have shown ruxolitinib effective in symptom relief and hematocrit control for hydroxyurea-resistant polycythemia vera, but its role in disease progression is not yet clear.

With further research, a selection of combination therapies could increase patient response in various cancer types.

Aldo-keto reductase 1C3 (AKR1C3) has been identified as a potential biomarker and target in several cancers, and a recent study found it to be a potential biomarker in T acute lymphoblastic leukemia/lymphoma (T-ALL).

Continual nutrition modification is crucial in patients with moderate to advanced chronic kidney disease (CKD), and more interactive at-home solutions hold potential to improve nutritional nursing models after hospital discharge. 

Chronic kidney disease is a common complication in multiple myeloma, and a recent study found it is safe to treat this patient population with autologous stem cell transplantation.

Self-reported vaccination statuses are often used in studies of influenza vaccination, and a recent study found this method reliable in health care personnel who receive the vaccine consistently. 

Mesenchymal stem cells are known to promote tumor growth and metastasis in multiple myeloma (MM), but a recent study found they may also inhibit the effects of the corticosteroid dexamethasone, a common medication for the hematologic malignancy.

Monitoring glycemia in chronic kidney disease comes with challenges, but emerging strategies warrant more research in this patient population.

With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.

As more bacterial DNA sequences are identified, the computational challenges associated with whole-genome sequencing have researchers looking to other potential methods of tracking and understanding differences in bacterial pathogens such as Clostridioides difficile.

A recent study on Hispanics/Latinos in the United States found that lower potassium intake and higher sodium-to-potassium ratios may be more predictive of chronic kidney disease risk.

While studies have explored risks among patients with multiple myeloma, recent research is the first to compare cardiovascular mortality risk in multiple myeloma to that of the general population.

Kleine-Levin syndrome is rare and difficult to diagnose, especially when symptoms are atypical. Recent research points to LMOD3 variations as a potential diagnostic marker if confirmed by further research.

Analyzing whole-mount histologic large sections is not a new practice, but a new strategy was needed to fully characterize peripheral nerve invasion in hilar cholangiocarcinoma.

Cross-border acquisition of medications such as antibiotics has long been a practice in US communities bordering Mexico, and a lack of sufficient insurance is one driver of the trend, according to a recent study.

Despite underrepresentation in clinical trials of acute coronary syndrome treatments, a recent study suggests treatment strategies and outcomes in chronic kidney disease patients with ST-elevation myocardial infarctions (STEMI) have improved over time.

With further research, allogeneic CAR T-cell therapy may help overcome the cost and production time barriers currently associated with autologous CAR T-cell therapy.